Comparative breakthrough: Umbilical cord mesenchymal stem cells vs bone marrow mesenchymal stem cells in heart failure treatment

doi:10.4330/wjc.v16.i12.776

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Sum=3

Dec 26, 2024 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Cardiol. Dec 26, 2024; 16(12): 776-780
Published online Dec 26, 2024. doi: 10.4330/wjc.v16.i12.776

Comparative breakthrough: Umbilical cord mesenchymal stem cells vs bone marrow mesenchymal stem cells in heart failure treatment

Peng Li

Peng Li, Department of Geriatics, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China

Author contributions: Li P performed the research and wrote this manuscript.

Supported by National High Level Hospital Clinical Research Funding Project, No. BJ-2023-206.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Peng Li, MD, Doctor, Department of Geriatics, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dongdan, Dahua Road, Dongcheng District, Beijing 100730, China. lipbenzi@126.com

Received: August 6, 2024
Revised: September 21, 2024
Accepted: November 6, 2024
Published online: December 26, 2024
Processing time: 112 Days and 6.6 Hours

Core Tip

Core Tip: This article provides a comparative analysis of umbilical cord-derived mesenchymal stem cells (UC-MSCs) and bone marrow-derived mesenchymal stem cells (BM-MSCs) for the treatment of heart failure. UC-MSCs significantly increase left ventricular ejection fraction and exhibit a favorable safety profile, positioning them as a promising alternative to BM-MSCs. Future research should focus on optimizing administration protocols and understanding the long-term benefits of UC-MSCs in cardiac therapy.